Octapharma AG - Strategic SWOT Analysis Review

Date: July 5, 2017
Pages: 29
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OE151A78EEDEN
Leaflet:

Download PDF Leaflet

Octapharma AG - Strategic SWOT Analysis Review
Octapharma AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Octapharma AG (Octapharma) is a human protein manufacturer that focuses on developing and producing human proteins from human plasma and cell lines. The company treats patients worldwide with products across haematology (coagulation disorders), immunotherapy (immune disorders) and critical care therapeutic areas. It sources majority of plasma from company-owned donation centers. Octapharma owns plasma donation centers in the USA and in Germany, and owns six state-of-the-art production facilities in Austria, Germany, France, Mexico and Sweden. The company’s production plants carry out plasma fractionation and purification, pharmaceutical production, research and development, product labelling, packaging, storage and distribution. Octapharma is headquartered in Lachen, Switzerland.

Octapharma AG Key Recent Developments

Mar 01,2017: Octapharma Group Publishes 2016 Annual Results Reporting Revenue of €1.6 Billion and Operating Income of €383 Million
Oct 17,2016: Octapharma Selects Cardinal Health as Authorized Distributor for Product Portfolio in Puerto Rico
Jul 22,2016: Octapharma to sponsor two symposia at the 2016 World Federation of Hemophilia (WFH) World Congress in Orlando, USA
Mar 08,2016: Octapharma Group publishes 2015 annual results reporting revenue of €1.5 billion and operating income of €351 million
Mar 07,2016: Zika Virus Guidance from FDA Notes Safety of Plasma Protein Products and the Availability of Octapharma’s Octaplas

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Octapharma AG - Key Facts
Octapharma AG - Key Employees
Octapharma AG - Major Products and Services
Octapharma AG - History
Octapharma AG - Company Statement
Octapharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Octapharma AG - Business Description
Octapharma AG - Corporate Strategy
Octapharma AG - SWOT Analysis
SWOT Analysis - Overview
Octapharma AG - Strengths
Octapharma AG - Weaknesses
Octapharma AG - Opportunities
Octapharma AG - Threats
Octapharma AG - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Octapharma AG, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Mar 01, 2017: Octapharma Group Publishes 2016 Annual Results Reporting Revenue of €1.6 Billion and Operating Income of €383 Million
Oct 17, 2016: Octapharma Selects Cardinal Health as Authorized Distributor for Product Portfolio in Puerto Rico
Jul 22, 2016: Octapharma to sponsor two symposia at the 2016 World Federation of Hemophilia (WFH) World Congress in Orlando, USA
Mar 08, 2016: Octapharma Group publishes 2015 annual results reporting revenue of €1.5 billion and operating income of €351 million

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Octapharma AG, Key Facts
Octapharma AG, Key Employees
Octapharma AG, Major Products and Services
Octapharma AG, History
Octapharma AG, Other Locations
Octapharma AG, Subsidiaries
Octapharma AG, Key Competitors
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Octapharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Octapharma AG, Recent Deals Summary

LIST OF FIGURES

Octapharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Octapharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

ProMetic Life Sciences Inc
Polyneuron Pharmaceuticals AG
Neurimmune Holding AG
Grifols Inc
CSL Ltd
China Biologic Products Inc
Benesis Corp
Abeona Therapeutics Inc
Skip to top


Ask Your Question

Octapharma AG - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: